p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells

Luis A. Martinez, Jun Yang, Elba S. Vazquez, María Del Carmen Rodriguez-Vargas, Matilde Olive, Jer Tsong Hsieh, Christopher J. Logothetis, Nora M. Navone

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease. Doxorubicin (Dx), an anthracycline used commonly as a chemotherapeutic agent in relapsed prostate cancer, is a strong inducer of p53 expression and p21CIP1/WAF1 (p21) transactivation. Previous reports suggest that p21 may have a role in the modulation to chemotherapy-induced apoptosis, prostate cancer progression and androgen regulation. In order to investigate if p21 has a pro-survival role in the response of prostate cancer cells to cellular stress, we exposed two androgen-regulated human prostate cancer cell lines (MDA PCa 2b and LNCaP) to Dx and growth factor withdrawal. We then studied expression of p53 and p21, cell-cycle kinetics and apoptosis. We have found that p53 protein accumulated in a dose-and time-dependent manner after Dx treatment, while p21 expression increased over time with low but decreased with high Dx doses. Apoptosis occurred in parallel with p21 down-modulation. Dx treatment of p53 knockout cells demonstrated that p21 induction was strictly p53 dependent. Reduction of p21 levels in prostate cancer cells with an antisense p21 adenovirus resulted in sensitization to Dx and accelerated onset of apoptosis in response to growth factor withdrawal. The evidence presented here also suggests that caspase activation mediates the apoptosis in this system and supports that p21 may modulate the threshold of apoptosis in prostate cancer. These observations may thus provide implications onto the integration of chemotherapy and androgen ablation.

Original languageEnglish (US)
Pages (from-to)1289-1296
Number of pages8
JournalCarcinogenesis
Volume23
Issue number8
StatePublished - 2002

Fingerprint

DNA Damage
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins
Doxorubicin
Apoptosis
Androgens
Drug Therapy
Anthracyclines
Caspases
Adenoviridae
Transcriptional Activation
Cell Cycle
Therapeutics
Recurrence
Cell Line
Proteins

ASJC Scopus subject areas

  • Cancer Research

Cite this

Martinez, L. A., Yang, J., Vazquez, E. S., Rodriguez-Vargas, M. D. C., Olive, M., Hsieh, J. T., ... Navone, N. M. (2002). p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis, 23(8), 1289-1296.

p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. / Martinez, Luis A.; Yang, Jun; Vazquez, Elba S.; Rodriguez-Vargas, María Del Carmen; Olive, Matilde; Hsieh, Jer Tsong; Logothetis, Christopher J.; Navone, Nora M.

In: Carcinogenesis, Vol. 23, No. 8, 2002, p. 1289-1296.

Research output: Contribution to journalArticle

Martinez, LA, Yang, J, Vazquez, ES, Rodriguez-Vargas, MDC, Olive, M, Hsieh, JT, Logothetis, CJ & Navone, NM 2002, 'p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells', Carcinogenesis, vol. 23, no. 8, pp. 1289-1296.
Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas MDC, Olive M, Hsieh JT et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002;23(8):1289-1296.
Martinez, Luis A. ; Yang, Jun ; Vazquez, Elba S. ; Rodriguez-Vargas, María Del Carmen ; Olive, Matilde ; Hsieh, Jer Tsong ; Logothetis, Christopher J. ; Navone, Nora M. / p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. In: Carcinogenesis. 2002 ; Vol. 23, No. 8. pp. 1289-1296.
@article{3dce18e56178408a8aa5bdad1e8168b5,
title = "p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells",
abstract = "Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease. Doxorubicin (Dx), an anthracycline used commonly as a chemotherapeutic agent in relapsed prostate cancer, is a strong inducer of p53 expression and p21CIP1/WAF1 (p21) transactivation. Previous reports suggest that p21 may have a role in the modulation to chemotherapy-induced apoptosis, prostate cancer progression and androgen regulation. In order to investigate if p21 has a pro-survival role in the response of prostate cancer cells to cellular stress, we exposed two androgen-regulated human prostate cancer cell lines (MDA PCa 2b and LNCaP) to Dx and growth factor withdrawal. We then studied expression of p53 and p21, cell-cycle kinetics and apoptosis. We have found that p53 protein accumulated in a dose-and time-dependent manner after Dx treatment, while p21 expression increased over time with low but decreased with high Dx doses. Apoptosis occurred in parallel with p21 down-modulation. Dx treatment of p53 knockout cells demonstrated that p21 induction was strictly p53 dependent. Reduction of p21 levels in prostate cancer cells with an antisense p21 adenovirus resulted in sensitization to Dx and accelerated onset of apoptosis in response to growth factor withdrawal. The evidence presented here also suggests that caspase activation mediates the apoptosis in this system and supports that p21 may modulate the threshold of apoptosis in prostate cancer. These observations may thus provide implications onto the integration of chemotherapy and androgen ablation.",
author = "Martinez, {Luis A.} and Jun Yang and Vazquez, {Elba S.} and Rodriguez-Vargas, {Mar{\'i}a Del Carmen} and Matilde Olive and Hsieh, {Jer Tsong} and Logothetis, {Christopher J.} and Navone, {Nora M.}",
year = "2002",
language = "English (US)",
volume = "23",
pages = "1289--1296",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells

AU - Martinez, Luis A.

AU - Yang, Jun

AU - Vazquez, Elba S.

AU - Rodriguez-Vargas, María Del Carmen

AU - Olive, Matilde

AU - Hsieh, Jer Tsong

AU - Logothetis, Christopher J.

AU - Navone, Nora M.

PY - 2002

Y1 - 2002

N2 - Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease. Doxorubicin (Dx), an anthracycline used commonly as a chemotherapeutic agent in relapsed prostate cancer, is a strong inducer of p53 expression and p21CIP1/WAF1 (p21) transactivation. Previous reports suggest that p21 may have a role in the modulation to chemotherapy-induced apoptosis, prostate cancer progression and androgen regulation. In order to investigate if p21 has a pro-survival role in the response of prostate cancer cells to cellular stress, we exposed two androgen-regulated human prostate cancer cell lines (MDA PCa 2b and LNCaP) to Dx and growth factor withdrawal. We then studied expression of p53 and p21, cell-cycle kinetics and apoptosis. We have found that p53 protein accumulated in a dose-and time-dependent manner after Dx treatment, while p21 expression increased over time with low but decreased with high Dx doses. Apoptosis occurred in parallel with p21 down-modulation. Dx treatment of p53 knockout cells demonstrated that p21 induction was strictly p53 dependent. Reduction of p21 levels in prostate cancer cells with an antisense p21 adenovirus resulted in sensitization to Dx and accelerated onset of apoptosis in response to growth factor withdrawal. The evidence presented here also suggests that caspase activation mediates the apoptosis in this system and supports that p21 may modulate the threshold of apoptosis in prostate cancer. These observations may thus provide implications onto the integration of chemotherapy and androgen ablation.

AB - Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease. Doxorubicin (Dx), an anthracycline used commonly as a chemotherapeutic agent in relapsed prostate cancer, is a strong inducer of p53 expression and p21CIP1/WAF1 (p21) transactivation. Previous reports suggest that p21 may have a role in the modulation to chemotherapy-induced apoptosis, prostate cancer progression and androgen regulation. In order to investigate if p21 has a pro-survival role in the response of prostate cancer cells to cellular stress, we exposed two androgen-regulated human prostate cancer cell lines (MDA PCa 2b and LNCaP) to Dx and growth factor withdrawal. We then studied expression of p53 and p21, cell-cycle kinetics and apoptosis. We have found that p53 protein accumulated in a dose-and time-dependent manner after Dx treatment, while p21 expression increased over time with low but decreased with high Dx doses. Apoptosis occurred in parallel with p21 down-modulation. Dx treatment of p53 knockout cells demonstrated that p21 induction was strictly p53 dependent. Reduction of p21 levels in prostate cancer cells with an antisense p21 adenovirus resulted in sensitization to Dx and accelerated onset of apoptosis in response to growth factor withdrawal. The evidence presented here also suggests that caspase activation mediates the apoptosis in this system and supports that p21 may modulate the threshold of apoptosis in prostate cancer. These observations may thus provide implications onto the integration of chemotherapy and androgen ablation.

UR - http://www.scopus.com/inward/record.url?scp=0036045455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036045455&partnerID=8YFLogxK

M3 - Article

C2 - 12151346

AN - SCOPUS:0036045455

VL - 23

SP - 1289

EP - 1296

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 8

ER -